Thymosin Alpha-1

Thymosin Alpha-1 - Immunomodulatory Research Peptide

Thymosin Alpha-1 (Talpha1), also known under its INN thymalfasin, is a 28-amino-acid peptide originally isolated from the thymus gland in 1977. It is one of the most characterized immunomodulatory peptides in research literature and is the active component of the approved drug Zadaxin (used in several countries outside the US for hepatitis B and C). The peptide’s primary research profile is on T-cell maturation and innate-immune signaling - which is why it sits in the “immune-support” category alongside peptides like LL-37 but on a different mechanistic axis.

Why Thymosin Alpha-1’s Profile Matters

Unlike direct antimicrobial peptides, Thymosin Alpha-1 does not attack pathogens itself. It modulates the immune system’s response - supporting T-cell differentiation, upregulating Toll-like receptor signaling in dendritic cells, and increasing NK-cell activity. That makes it a tool for studies that want to characterize immune calibration rather than direct pathogen killing.

Thymosin Alpha-1 vs TB-500 (Thymosin Beta-4)

The two “thymosin” peptides share a name and a tissue of origin but are mechanistically unrelated. They regularly get compared, so the distinction matters.

Research Applications

Thymosin Alpha-1 is used in studies examining:

• T-cell maturation and adaptive-immunity calibration
• Dendritic-cell Toll-like receptor 9 signaling
• NK-cell activity and cytokine balance
• Chronic viral-infection models (hepatitis B/C literature is the largest body)
• Vaccine-response and immune-senescence endpoints
• Comparative research vs. other immunomodulators

Specifications

Storage & Handling

Unopened vials are kept at 2-8°C under standard cold-chain conditions and remain stable for 12+ months. Reconstitution parameters, solvent compatibility, and post-reconstitution stability for Thymosin Alpha-1 are documented in the published peer-reviewed literature and standard peptide-chemistry references.

Reference Literature

Published clinical and preclinical Thymosin Alpha-1 literature is available through PubMed, Google Scholar, and other peer-reviewed databases. WWP does not provide protocol design, dosing guidance, or administration parameters. Those decisions rest with the researcher and any applicable institutional review board.

Common Questions About Thymosin Alpha-1 Research

What is Thymosin Alpha-1 used for in research?

It is most commonly studied as an immunomodulator. Published work covers T-cell maturation, dendritic-cell TLR9 signaling, NK-cell activity, cytokine balance, and chronic viral infection models (notably hepatitis B and C). It does not kill pathogens directly - it tunes the immune response.

What is the difference between TB-500 and Thymosin Alpha-1?

They share a name and a tissue of origin but are mechanistically unrelated. Thymosin Alpha-1 is a 28-amino-acid immunomodulatory peptide. TB-500 is a fragment of Thymosin Beta-4, a 43-amino-acid actin-binding peptide studied for tissue repair. They are not interchangeable and do not pair in the same study designs.

What is thymalfasin?

Thymalfasin is the international nonproprietary name (INN) for Thymosin Alpha-1 - the same molecule. Zadaxin is the brand name under which thymalfasin is approved in several countries outside the United States.

Is Thymosin Alpha-1 FDA approved?

No. Thymosin Alpha-1 (thymalfasin / Zadaxin) is not FDA approved for any use in the United States. It is approved in several other countries for specific indications. Every vial WWP ships is labeled and sold strictly for laboratory and research use only.

How is Thymosin Alpha-1 stored?

Unopened vials are stored at 2-8°C and stay stable for 12+ months. Once reconstituted with bacteriostatic water, the solution is kept at 2-8°C and used within 28-30 days.

Purity Guarantee

Every batch is ≥99% purity. Send us a COA from any independent test and we’ll issue store credit regardless of what it shows.